Ornidazole + OfloxacinThird Party Manufacturing in India

Ornidazole + Ofloxacin works by a dual antimicrobial action where ofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting replication, while ornidazole interacts with microbial DNA to cause helical structure breakage and cell death. It binds to essential replication proteins and nucleic acids to help the body eliminate mixed aerobic and anaerobic infections. Unlike single-agent therapies, it provides broad-spectrum coverage covering protozoa, Gram-negative, and Gram-positive pathogens. It is highly effective and well-tolerated.

Therapeutic Uses

• Mixed Intra-abdominal Infections: Resolves complex abdominal tissue infections involving aerobic and anaerobic bacteria.
• Pelvic Inflammatory Disease: Treats acute mixed bacterial infections of the female reproductive tract.
• Post-Surgical Prophylaxis: Prevents bacterial contamination during and after colorectal or gynecological surgeries.

Why Manufacturers Choose Ornidazole + Ofloxacin

Ornidazole + Ofloxacin third party manufacturing in India represents a highly lucrative commercial segment because of the widespread clinical need for empirical therapy in mixed infections. Celesta utilizes advanced sterile filling lines at WHO-GMP certified partner plants to produce stable, crystal-free large volume parenterals. This reliable supply chain and quality standard make it a highly requested combination for institutional supply and hospital distribution.